Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 2
1975 5
1976 4
1977 14
1978 9
1979 5
1980 14
1981 9
1982 13
1983 11
1984 15
1985 9
1986 10
1987 8
1988 16
1989 16
1990 11
1991 16
1992 19
1993 23
1994 28
1995 29
1996 36
1997 45
1998 34
1999 39
2000 56
2001 27
2002 37
2003 50
2004 57
2005 69
2006 67
2007 68
2008 57
2009 54
2010 53
2011 58
2012 57
2013 41
2014 32
2015 28
2016 40
2017 28
2018 20
2019 23
2020 17
2021 19
2022 16
2023 18
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

1,333 results

Results by year

Filters applied: . Clear all
Page 1
Valproic acid as adjuvant treatment for convulsive status epilepticus: a randomised clinical trial.
Sharshar T, Porcher R, Asfar P, Grimaldi L, Jabot J, Argaud L, Lebert C, Bollaert PE, Harlay ML, Chillet P, Maury E, Santoli F, Blanc P, Sonneville R, Vu DC, Rohaut B, Mazeraud A, Alvarez JC, Navarro V, Clair B, Outin H; Valse investigators and for the Groupe d’Explorations Neurologiques en Reanimation (GENER). Sharshar T, et al. Crit Care. 2023 Jan 9;27(1):8. doi: 10.1186/s13054-022-04292-7. Crit Care. 2023. PMID: 36624526 Free PMC article. Clinical Trial.
The objective was to determine whether valproic acid (VPA) as complementary treatment to the stepwise strategy improves the outcomes of patients with de novo established GCSE. ...
The objective was to determine whether valproic acid (VPA) as complementary treatment to the stepwise strategy improves the ou …
Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial.
Georgoff PE, Nikolian VC, Bonham T, Pai MP, Tafatia C, Halaweish I, To K, Watcharotone K, Parameswaran A, Luo R, Sun D, Alam HB. Georgoff PE, et al. Clin Pharmacokinet. 2018 Feb;57(2):209-219. doi: 10.1007/s40262-017-0553-1. Clin Pharmacokinet. 2018. PMID: 28497259 Free PMC article. Clinical Trial.
BACKGROUND: Valproic acid, a histone deacetylase inhibitor, has beneficial effects in the setting of cancer, neurologic diseases, and traumatic injuries. In animal models of traumatic injury, a single dose of valproic acid has been shown to reduce mort …
BACKGROUND: Valproic acid, a histone deacetylase inhibitor, has beneficial effects in the setting of cancer, neurologic diseas …
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. Bilen MA, et al. Cancer Chemother Pharmacol. 2015 Apr;75(4):869-74. doi: 10.1007/s00280-015-2695-x. Epub 2015 Feb 10. Cancer Chemother Pharmacol. 2015. PMID: 25666183 Clinical Trial.
PURPOSE: The objectives of this study were to evaluate the tolerability and efficacy of valproic acid (VPA) and lenalidomide. METHODS: In this 3+3 design study, VPA was administered daily on a 7-day-on, 7-day-off schedule, and lenalidomide was administered daily for …
PURPOSE: The objectives of this study were to evaluate the tolerability and efficacy of valproic acid (VPA) and lenalidomide. …
Safety and efficacy of valproic acid treatment in SCA3/MJD patients.
Lei LF, Yang GP, Wang JL, Chuang DM, Song WH, Tang BS, Jiang H. Lei LF, et al. Parkinsonism Relat Disord. 2016 May;26:55-61. doi: 10.1016/j.parkreldis.2016.03.005. Epub 2016 Mar 12. Parkinsonism Relat Disord. 2016. PMID: 26997655 Clinical Trial.
In Drosophila and rat models of polyQ diseases, histone deacetylation (HDAC) inhibitors improved locomotor function and survival time by increasing histone acetylation levels and modulating gene expression. Valproic acid (VPA) is a pan-HDAC inhibitor used clinically …
In Drosophila and rat models of polyQ diseases, histone deacetylation (HDAC) inhibitors improved locomotor function and survival time by inc …
Phenobarbital--valporic acid interaction.
Patel IH, Levy RH, Cutler RE. Patel IH, et al. Clin Pharmacol Ther. 1980 Apr;27(4):515-21. doi: 10.1038/clpt.1980.72. Clin Pharmacol Ther. 1980. PMID: 6766833 Clinical Trial.
In the other, subjects received 250 mg valproic acid orally twice daily for 14 consecutive days and a 60-mg dose of phenobarbital orally on day 4. ...The findings indicate that valproic acid inhibits phenobarbital metabolism....
In the other, subjects received 250 mg valproic acid orally twice daily for 14 consecutive days and a 60-mg dose of phenobarbi …
Valproic acid in epilepsy: clinical and pharmacological effects.
Mattson RH, Cramer JA, Williamson PD, Novelly RA. Mattson RH, et al. Ann Neurol. 1978 Jan;3(1):20-5. doi: 10.1002/ana.410030105. Ann Neurol. 1978. PMID: 350128 Clinical Trial.
The antiepileptic drug valproic acid was studied in an open clinical trial as adjunct medication for 23 patients with uncontrolled seizures of a generalized or partial type. ...This observation was interpreted as a drug interaction: valproic acid compe …
The antiepileptic drug valproic acid was studied in an open clinical trial as adjunct medication for 23 patients with uncontro …
Therapeutic drug monitoring of valproic acid.
Shaikh AS, Liu H, Li Y, Cao L, Guo R. Shaikh AS, et al. Pak J Pharm Sci. 2018 Jul;31(4(Special)):1773-1776. Pak J Pharm Sci. 2018. PMID: 30203778 Clinical Trial.
The unpredictable and unfavorable connection of dose and plasma concentration of valproic acid supports the necessity to regularly measure its plasma concentration. The present study is drug monitoring of valproic acid and comparative evaluation of the …
The unpredictable and unfavorable connection of dose and plasma concentration of valproic acid supports the necessity to regul …
Drug therapy: Valproic acid.
Koch-Weser J, Browne TR. Koch-Weser J, et al. N Engl J Med. 1980 Mar 20;302(12):661-6. doi: 10.1056/NEJM198003203021204. N Engl J Med. 1980. PMID: 6766529 Review. No abstract available.
No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers.
Cawello W, Bonn R. Cawello W, et al. J Clin Pharmacol. 2012 Nov;52(11):1739-48. doi: 10.1177/0091270011426875. Epub 2011 Dec 8. J Clin Pharmacol. 2012. PMID: 22162508 Clinical Trial.
Two open-label, randomized, multiple-dose clinical studies evaluated the potential for pharmacokinetic interaction between the antiepileptic drugs lacosamide and valproic acid. The influence of lacosamide on valproic acid pharmacokinetics (trial A) and …
Two open-label, randomized, multiple-dose clinical studies evaluated the potential for pharmacokinetic interaction between the antiepileptic …
1,333 results